<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230823059229N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-02-28</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Investigation the Effect of Active Vision Therapy Using Vision Therapy System 4 (VTS4) in Bilateral Refractive Amblyopia</public_title>
      <acronym></acronym>
      <scientific_title>Investigation the Effect of Active Vision Therapy on visual skills using Vision Therapy System 4 (VTS4) in children with Bilateral Refractive Amblyopia ages 5-13</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-03-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74330</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: patient divide in two control and active treatment groups. Block Randomization is used for this. Blocks of couple of four are created in which, randomly, half of the people in each group are placed in one block and the others in the other group. Using blocks of couple of four, we will place 40 people in two control and treatment groups. First, we determine all the four states in which group.
We consider the treatment group as A and the control group as B.
1-AABB
2-ABBA
3-ABAB
4-BBAA
5-BABA
6-BAAB
Then, we will randomly select 8 blocks of four and write their combination one after the other, in fact, we will sample 8 times from this 6-member society, that is, a random number between 1 and 6 will be selected 8 times. In this way, the type of treatment will be determined for 40 patients, Blinding description: It will be made in a double-blind manner. In order for the researcher not to know whether the examinee is in the active or inactive vision therapy group, vision therapy will be performed by one person and the main researcher will perform other examinations. In order to blind the participants , we will also consider sessions to perform placebo vision therapy exercises in the office for the patching group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>amblyopia, lazy eye.</hc_freetext>
      <i_freetext>Intervention 1: "Intervention group:" Patching and Vision therapy exercises in three sessions of 30 minutes a week with the Vision Therapy System version 4 (an American software (HTS Inc., Gold Canyon, AZ, USA))، consisting of a 50-inch monitor, a case, a gamepad and a pair of liquid crystal glasses and patching eye. Intervention 2: "Control group:" 1-2 hours patching each eye every day and placebo training.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information about  the primary outcome measure  can be shared.

When:
starting 6 months after publication

To whom:
available for people working in academic institutions and people working in businesses can apply to receive it.

Conditions:
without limitation

Where to obtain:
Saeedeh Hosseinmenni, researcher of  the study:
s.hoseiny2021@gmail .com

How to obtain:
Two months after application

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Saeedeh Hosseinmenni</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rehabilitation school of SBMU, Damavand St, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1616913111</zip>
        <telephone>+98 21 7756 1721</telephone>
        <email>s.hoseiny2021@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Saeedeh Hoseinmenni</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>N 105., floor 1., Otana Flat, Maali Abad BVL, Shiraz</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7187711733</zip>
        <telephone>+98 71 3634 1939</telephone>
        <email>s_hoseiny2008@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Full patient consent to participate in the study
The minimum age is 5 and the maximum is 13 years
Bilateral refractive amblyopes
Astigmatism more than 1.5 diopters and hyperopia more than 3.00 diopters in each eye or a mix hyperopia-stigmatism
Maximum vision 20/40 and minimum vision 20/100 in each eye (moderate amblyopia)</inclusion_criteria>
      <agemin>5 years</agemin>
      <agemax>13 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Children who do not cooperate to perform the tests
Children who experience diplopia or nausea while using liquid crystal glasses
The presence of uncompensated phoria
Children who do not have the necessary follow-up for treatment.
The existence of pathological and structural problems of the eye
History of eye surgeries
The presence of nystagmus
strabismus, microtropia or eccentric fixation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H53.023</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Refractive amblyopia, bilateral,</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>"Intervention group:" Patching and Vision therapy exercises in three sessions of 30 minutes a week with the Vision Therapy System version 4 (an American software (HTS Inc., Gold Canyon, AZ, USA))، consisting of a 50-inch monitor, a case, a gamepad and a pair of liquid crystal glasses and patching eye</i_keyword>
      <i_keyword>"Control group:" 1-2 hours patching each eye every day and placebo training</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Visual acuity. Timepoint: before and after. Method of measurement: snellen vision chart LCD chart vision (model, HDC-9000N/PF, made in South Korea) Howitz company.</prim_outcome>
      <prim_outcome>Stereoacuity. Timepoint: before and after. Method of measurement: Randot &amp;; Vectogram  Registered trade marks of Stereo Optical Co., Inc and Stereo Fly Stereotest of Stereo Optical Company Inc.</prim_outcome>
      <prim_outcome>Contrast sensitivity. Timepoint: before and after. Method of measurement: Freiburg contrast sensitivity test, made in Germany, designed by Michael Bach, 2011 version.</prim_outcome>
      <prim_outcome>Infacility of Accommodation. Timepoint: Before and after. Method of measurement: flipper lens and snellen near chart.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-11-26</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti university of medical sciences</contact_name>
        <contact_address>floor. 13, flat A, he central headquarters of the Ministry of Health, Simayr Iran street, Shahrak Ghods, Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
